Insomnia is a common disease, which can be mild to severe and can make it difficult for people to fall asleep or sleep soundly. This condition can be chronic or acute, and causes affected individuals to have short or poor quality sleep. Lack of sleep can cause other symptoms, such as difficulty concentrating, anxiety, depression, and irritability. 1 in 3 adults sometimes suffers from insomnia, and 1 in 10 adults suffers from chronic insomnia.
Acute insomnia is a symptom or side effect of mood disorders, neurological disorders, or other medical or sleep disorders, while primary or chronic insomnia is a disorder that itself is generally triggered by long-term stress or emotional upset.
Lifestyle changes, including good sleep habits, often help reduce acute insomnia. On the other hand, the treatment of chronic insomnia often requires cognitive-behavioral therapy, which targets thoughts and actions that disrupt sleep and focuses on reducing sleep anxiety; and/or the use of short-term or long-term prescription drugs.
Drugs used to treat insomnia often cause side effects, including feeling weak in the morning, and rarely sleeping while eating, sleepwalking, or driving.
Zaleplon (Zaleplon) is a short-acting, non-benzodiazepine GABA agonist hypnotics indicated for the short-term treatment of insomnia, and is available in the United States in the form of immediate-release 5mg and 10mg capsules under the trade name Sonata® is sold, and its main composition intermediate is N-Ethyl Acetamide. It is a non-benzodiazepine hypnotic and is currently indicated for short-term insomnia. This drug is currently characterized by rapid absorption (providing rapid fall asleep) and rapid elimination, thereby avoiding residual effects, but is associated with poor sleep maintenance.
